Literature DB >> 11312686

Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents.

J Wu1, M E Lizarzaburu, M J Kurth, L Liu, H Wege, M A Zern, M H Nantz.   

Abstract

In vivo gene delivery mediated by cationic lipids is often compromised by aggregation due to complexation with proteins in the blood. To improve the stability of cationic lipid-DNA complexes, the present study aimed to develop a novel approach in which a poly(cationic lipid) (PCL) is utilized to form stable cationic polyplexes for gene transfection. Hydrogenation of the acrylamide analogue of betaAE-DMRI, the polymerizable precursor of PCL, provided a monomeric lipid derivative (MHL) which was used for direct comparison of corresponding lipoplex stability, toxicity, and transfection activity. Various formulations of cationic liposomes, such as MHL, MHL-cholesterol (Chol), PCL, PCL-Chol, DOTAP-Chol, and commercially available lipofectamine were generated and examined in this study. The new poly(cationic lipid) did not display any significant toxicity to rat hepatocytes or Hep G2 cells as indicated by an LDH leakage assay. Furthermore, PCL was significantly less toxic than MHL, DOTAP-Chol or lipofectamine. Suspensions of PCL were resistant to aggregation even after 24 h of exposure to solutions containing 50 and 100% fetal bovine serum (FBS). In contrast, suspensions of lipofectamine extensively aggregated after 24 h of exposure to 50% FBS. To examine the influence of lipid polymerization on gene transfer activity, liposome-mediated transfections of a luciferase vector (pGL3) were performed in Hep G2 and Alexander cell lines. The luciferase activity of the PCL formulations in Hep G2 cells were similar to those of the MHL, DOTAP-Chol and lipofectamine formulations, demonstrating that lipid polymerization does not compromise transfection activity. In comparison to the monomeric precursor MHL and to the industry transfection standards DOTAP and lipofectamine, the novel poly(cationic lipid) exhibited the lowest cytotoxicity, was the most resistant to serum-induced aggregation and had comparable transfection activity when coformulated with cholesterol. This novel polymerization approach for the development of stable and active polyplexes may prove a valuable alternative for in vivo gene delivery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312686     DOI: 10.1021/bc000097e

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  9 in total

Review 1.  Non-viral based miR delivery and recent developments.

Authors:  Annalise Elizabeth Labatut; George Mattheolabakis
Journal:  Eur J Pharm Biopharm       Date:  2018-04-19       Impact factor: 5.571

2.  N4,N9-dioleoyl spermine is a novel nonviral lipopolyamine vector for plasmid DNA formulation.

Authors:  Osama A A Ahmed; Noppadon Adjimatera; Charareh Pourzand; Ian S Blagbrough
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

Review 3.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

4.  Physico-chemical characterization of polylipid nanoparticles for gene delivery to the liver.

Authors:  Maung T Nyunt; Christopher W Dicus; Yi-Yao Cui; M Cecilia Yappert; Thomas R Huser; Michael H Nantz; Jian Wu
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

5.  Well-defined degradable cationic polylactide as nanocarrier for the delivery of siRNA to silence angiogenesis in prostate cancer.

Authors:  Chih-Kuang Chen; Wing-Cheung Law; Ravikumar Aalinkeel; Bindukumar Nair; Atcha Kopwitthaya; Supriya D Mahajan; Jessica L Reynolds; Jiong Zou; Stanley A Schwartz; Paras N Prasad; Chong Cheng
Journal:  Adv Healthc Mater       Date:  2012-07-26       Impact factor: 9.933

6.  Gene Silencing of Human Neuronal Cells for Drug Addiction Therapy using Anisotropic Nanocrystals.

Authors:  Wing-Cheung Law; Supriya D Mahajan; Atcha Kopwitthaya; Jessica L Reynolds; Maixian Liu; Xin Liu; Guanying Chen; Folarin Erogbogbo; Lisa Vathy; Ravikumar Aalinkeel; Stanley A Schwartz; Ken-Tye Yong; Paras N Prasad
Journal:  Theranostics       Date:  2012-07-27       Impact factor: 11.556

Review 7.  Lipid-Based Nanocarriers for RNA Delivery.

Authors:  Hui Yi Xue; Pengbo Guo; Wu-Cheng Wen; Ho Lun Wong
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 8.  MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.

Authors:  Jana Merhautova; Regina Demlova; Ondrej Slaby
Journal:  Front Pharmacol       Date:  2016-09-27       Impact factor: 5.810

Review 9.  Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer.

Authors:  Virginia Campani; Giuseppina Salzano; Sara Lusa; Giuseppe De Rosa
Journal:  Nanomaterials (Basel)       Date:  2016-07-09       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.